SCHEMBL4222111

SCHEMBL4222111

O=C(C=Cc1cnc(Nc2cccc(NC(=O)C3CCCCC3)c2)c(Cl)c1)NOC1CCCCO1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 2/20 0.42
▸ BTK Q06187 2/20 0.40
▸ CCNA2 P20248 1/20 0.40
▸ CDK2 P24941 1/20 0.40
▸ CCNA1 P78396 1/20 0.40
▸ CDK5 Q00535 1/20 0.40
▸ CDK5R1 Q15078 1/20 0.40
▸ ABL1 P00519 1/20 0.39
▸ PDGFRB P09619 1/20 0.39
▸ BCR P11274 1/20 0.39
▸ SRC P12931 1/20 0.39
▸ PDGFRA P16234 1/20 0.39
▸ SIRT2 Q8IXJ6 1/20 0.38
▸ SIRT1 Q96EB6 1/20 0.38
▸ SIRT3 Q9NTG7 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ JAK2 O60674 3/20 0.38
▸ TYK2 P29597 3/20 0.38
▸ EPHX2 P34913 1/20 0.37
▸ KCNK3 O14649 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4222107 1.00 EGFR (0.42) EGFRBTKCCNA2CDK2CCNA1
SCHEMBL4232071 0.88 CCNA2 (0.39) EGFRCCNA2CDK2CCNA1CDK5
SCHEMBL4232075 0.88 CCNA2 (0.39) EGFRCCNA2CDK2CCNA1CDK5
Hydrochloric Acid SCHEMBL4226384 0.84 EGFR (0.48) EGFRABL1PDGFRBBCRSRC
Hydrochloric Acid SCHEMBL4226378 0.84 EGFR (0.48) EGFRABL1PDGFRBBCRSRC
SCHEMBL4222879 0.83 EGFR (0.50) EGFRABL1PDGFRBBCRSRC
SCHEMBL4222885 0.83 EGFR (0.50) EGFRABL1PDGFRBBCRSRC
SCHEMBL13428552 0.82 ALDH1A1 (0.37) CCNA2CDK2CCNA1CDK5CDK5R1
SCHEMBL4221748 0.79 CCNA2 (0.38) CCNA2CDK2CCNA1CDK5CDK5R1
SCHEMBL4221736 0.79 CCNA2 (0.38) CCNA2CDK2CCNA1CDK5CDK5R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7557127-B2 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2009-07-07 — — US disclosed
US-20090054464-A1 HDAC INHIBITOR ASTELLAS PHARMA INC. (JP) 2009-02-26 — — US disclosed
US-7465731-B2 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2008-12-16 — — US disclosed
US-20060052599-A1 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2006-03-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052599-A1 HDAC inhibitor HDAC1, HDAC2, HDAC11 EGFR 1368/4885BTK 1521/4885CCNA2 1568/4885
US-20090054464-A1 HDAC INHIBITOR HDAC1, HDAC2, HDAC8 EGFR 1493/4885BTK 1601/4885CCNA2 1204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback